Skip to main content
SpringerLink
Log in

Therapeutic targeting of IL-4-and IL-13-responsive cells in pulmonary fibrosis

  • Published:
Immunologic Research Aims and scope Submit manuscript

Abstract

Severe forms of idiopathic interstitial pneumonia (IIP), such as usual interstitial pneumonia (UIP), can be impervious to modern steroid and immunosuppressive treatment regimens, thereby emphasizing the need for novel effective therapies. Understanding the cytokine networks that may affect immune and structural cell activation and, hence, the progression of these fatal fibrotic diseases, has been a focus in our research. In this regard, we have examined the role of interleukin (IL)-4 and IL-13 and their respective receptor subunits in this process. Examination of clinical surgical lung biopsies (SLBs) showed that IIP is characterized by the abnormal, heightened expression of the receptor subunits that bind IL-4 and IL-13. Specifically, IL-4Rα and IL-13Rα2 (the high-affinity IL-13 receptor subunit) was present in greater abundance in SLBs and fibroblasts from IIP patients compared with normal patients, who exhibited no evidence of pulmonary fibrosis. These clinical findings prompted us to investigate whether the targeting of pulmonary cell types that were highly responsive to IL-4 and IL-13 was a viable therapeutic option in IIP. Using a chimeric protein comprised of human IL-13 and a truncated version of an exotoxin from Pseudomonas (abbreviated IL13-PE), we observed that IL13-PE selectively targeted human pulmonary fibroblasts grown from IIP SLBs, whereas it had a minimal effect on fibroblasts grown from biopsies from normal patients. In murine models characterized by abnormal airway or interstitial fibrotic responses, the intranasal administration of IL13-PE significantly attenuated the fibrotic response through the targeting of IL-4Rα-and IL-13Rα2-expressing pulmonary cells, including monocytes, macrophages, and pulmonary fibroblasts. Together, these data demonstrate that IL-4 and IL-13 are required for the initiation and maintenance of pulmonary fibrosis, and highlight the importance of further investigation of anti-fibrotic therapeutics that prevent the action of both cytokines during clinical pulmonary fibrosis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Green FH: Overview of pulmonary fibrosis. Chest 2002;122:334S-339S.

    Article  PubMed  Google Scholar 

  2. Travis W, Matsui K, Moss J, Ferrans V: Idiopathic nonspecific interstitial pneumonia: Prognostic significance of cellular and fibrosing patterns. Am J Surg Path 2000;24:19–33.

    Article  PubMed  CAS  Google Scholar 

  3. Katzenstein A, Myers J: Idiopathic pulmonary fibrosis. Clinical relevance of pathologic classification. Am J Respir Crit Care Med 1998;157:1301–1315.

    PubMed  CAS  Google Scholar 

  4. Myers JL: NSIP, UIP, and the ABCs of idiopathic interstitial pneumonias. Eur Respir J 1998;12:1003–1004.

    Article  PubMed  CAS  Google Scholar 

  5. American Thoracic Society, European Respiratory Society (ATS/ERS) international multidisciplinary consensus classification of idiopathic interstitial pneumonias. Am J Respir Crit Care Med 2002;165:277–304.

    Google Scholar 

  6. Nagai S, Kitaichi M, Itoh H, Nishimura K, Colby T: Idiopathic nonspecific interstitial pneumonia/fibrosis: comparison with idiopathic pulmonary fibrosis and BOOP. Eur Respir J 1998;12:1010–1019.

    Article  PubMed  CAS  Google Scholar 

  7. Daniil Z, Gilchrist F, Nicholson A, Hansell D, Harris J, Colby T, duBois R: A histologic pattern of nonspecific interstitial pneumonia is associated with a better prognosis than usual interstitial pneumonia in patients with cryptogenic fibrosing alveolitis. Am J Respir Crit Care Med 1999;160:899–905.

    PubMed  CAS  Google Scholar 

  8. Hampton J, Martinez F, Orens J, Toews G, Lynch III J: Corticosteroids in idiopathic pulmonary fibrosis (IPF): toxicity may outweight benefits. Am J Respir Crit Care Med 1994;149:A878.

    Google Scholar 

  9. Flaherty KR, Toews GB, Travis WD, Colby TV, Kazerooni EA, Gross BH, et al.: Clinical significance of histological classification of idiopathic interstitial pneumonia. Eur Respir J 2002;19:275–283.

    Article  PubMed  CAS  Google Scholar 

  10. Lasky JA, Brody AR: Interstitial fibrosis and growth factors. Environ Health Perspect 2000;108 Suppl 4:751–762.

    Article  PubMed  CAS  Google Scholar 

  11. Allen JT, Spiteri MA: Growth factors in idiopathic pulmonary fibrosis: relative roles. Respir Res 2002;3:13.

    Article  PubMed  Google Scholar 

  12. Coker RK, Laurent GJ: Pulmonary fibrosis: cytokines in the balance. Eur Respir J 1998;11:1218–1221.

    Article  PubMed  CAS  Google Scholar 

  13. Wallace WA, Ramage EA, Lamb D, Howie SE: A type 2 (Th2-like) pattern of immune response predominates in the pulmonary interstitium of patients with cryptogenic fibrosing alveolitis (CFA). Clin Exp Immunol 1995;101:436–441.

    PubMed  CAS  Google Scholar 

  14. Wallace WA, Howie SE: Immunoreactive interleukin 4 and interferon-gamma expression by type II alveolar epithelial cells in interstitial lung disease. J Pathol 1999;187:475–480.

    Article  PubMed  CAS  Google Scholar 

  15. Lukacs NW, Hogaboam C, Chensue SW, Blease K, Kunkel SL: Type 1/type 2 cytokine paradigm and the progression of pulmonary fibrosis. Chest 2001;120:5S-8S.

    Article  PubMed  CAS  Google Scholar 

  16. Gurujeyalakshmi G, Giri SN: Molecular mechanisms of anti-fibrotic effect of interferon gamma in bleomycinmouse model of lung fibrosis: down regulation of TGF-beta and procollagen I and III gene expression. Exp Lung Res 1995;21:791–808.

    Article  PubMed  CAS  Google Scholar 

  17. Segel MJ, Cohen PY, Izbicki G, Or R, Christensen TG, Wallach-Dayan SB, Breuer R: The role of interferon-{gamma} in the evolution of murine bleomycin lung fibrosis. Am J Physiol Lung Cell Mol Physiol 2003

  18. Ziesche R, Hofbauer E, Wittmann K, Petkov V, Block L: A preliminary study of long-term treatment with interferon gamma-1b and low-dose prednisone in patients with idiopathic pulmonary fibrosis. N Engl J Med 1999;341:1264–1269.

    Article  PubMed  CAS  Google Scholar 

  19. Prasse A, Muller KM, Kurz C, Hamm H, Virchow JC, Jr.: Does interferon-gamma improve pulmonary function in idiopathic pulmonary fibrosis? Eur Respir J 2003;22:906–911.

    Article  PubMed  CAS  Google Scholar 

  20. Raghu G, Brown KK, Bradford WZ, Starko K, Noble PW, Schwartz DA, King TE, Jr.: A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis. N Engl J Med 2004;350:125–133.

    Article  PubMed  CAS  Google Scholar 

  21. Postlethwaite AE, Holness MA, Katai H, Raghow R: Human fibroblasts synthesize elevated levels of extracellular matrix proteins in response to interleukin-4. J Clin Invest 1992;90:1479–1485.

    PubMed  CAS  Google Scholar 

  22. Gharaee-Kermani M, Denholm EM, Phan SH: Costimulation of fibroblast collagen and transforming growth factor betal gene expression by monocyte chemoattractant protein-1 via specific receptors. J Biol Chem 1996;271:17779–17784.

    Article  PubMed  CAS  Google Scholar 

  23. Hogaboam CM, Bone-Larson CL, Lipinski S, Lukacs NW, Chensue SW, Strieter RM, Kunkel SL. Differential monocyte chemoattractant protein-1 and chemokine receptor 2 expression by murine lung fibroblasts derived from Th1- and Th2-type pulmonary granuloma models. J Immunol 1999;163:2193–2201.

    PubMed  CAS  Google Scholar 

  24. Makhluf HA, Stepniakowska J, Hoffman S, Smith E, LeRoy EC, Trojanowska M. IL-4 upregulates tenascin synthesis in scleroderma and healthy skin fibroblasts. J Invest Dermatol 1996;107:856–859.

    Article  PubMed  CAS  Google Scholar 

  25. Postlethwaite AE, Seyer JM: Fibroblast chemotaxis induction by human recombinant interleukin-4. Identification by synthetic peptide analysis of two chemotactic domains residing in amino acid sequences 70–88 and 89–122. J Clin Invest 1991;87:2147–2152.

    PubMed  CAS  Google Scholar 

  26. Jakubzick C, Choi ES, Kunkel SL, Joshi BH, Puri RK, Hogaboam CM. Impact of interleukin-13 responsiveness on the synthetic and proliferative properties of Th1-and Th2-type pulmonary granuloma fibroblasts. Am J Pathol 2003;162:1475–1486.

    PubMed  CAS  Google Scholar 

  27. Zhu Z, Ma B, Zheng T, Homer RJ, Lee CG, Charo IF, et al.: IL-13-induced chemokine responses in the lung: role of CCR2 in the pathogenesis of IL-13-induced inflammation and remodeling. J Immunol 2002;168:2953–2462.

    PubMed  CAS  Google Scholar 

  28. Moore BB, Paine R, 3rd, Christensen PJ, Moore TA, Sitterding S, Ngan R, et al.: Protection from pulmonary fibrosis in the absence of CCR2 signaling. J Immunol 2001;167:4368–4377.

    PubMed  CAS  Google Scholar 

  29. Belperio JA, Dy M, Burdick MD, Xue YY, Li K, Elias JA, Keane MP. Interaction of IL-13 and C10 in the pathogenesis of bleomycin-induced pulmonary fibrosis. Am J Respir Cell Mol Biol 2002;27:419–427.

    PubMed  CAS  Google Scholar 

  30. Doucet C, Brouty-Boye D, Pottin-Clemenceau C, Canonica GW, Jasmin C, Azzarone B: Interleukin (IL) 4 and IL-13 act on human lung fibroblasts. Implication in asthma. J Clin Invest 1998;101:2129–2139.

    PubMed  CAS  Google Scholar 

  31. Doucet C, Brouty-Boye D, Pottin-Clemenceau C, Jasmin C, Canonica GW, Azzarone B: IL-4 and IL-13 specifically increase adhesion molecule and inflammatory cytokine expression in human lung fibroblasts. Int Immunol 1998;10:1421–1433.

    Article  PubMed  CAS  Google Scholar 

  32. Sempowski GD, Beckmann MP, Derdak S, Phipps RP: Subsets of murine lung fibroblasts express membrane-bound and soluble IL-4 receptors. Role of IL-4 in enhancing fibroblast proliferation and collagen synthesis. J Immunol 1994;152:3606–3614.

    PubMed  CAS  Google Scholar 

  33. Zhu Z, Homer RJ, Wang Z, Chen Q, Geba GP, Wang J, et al.: Pulmonary expression of interleukin-13 causes inflammation, mucus hypersecretion, subepithelial fibrosis, physiologic abnormalities, and eotaxin production. J Clin Invest 1999;103:779–788.

    PubMed  CAS  Google Scholar 

  34. Lee CG, Homer RJ, Zhu Z, Lanone S, Wang X, Koteliansky V, et al.: Interleukin-13 induces tissue fibrosis by selectively stimulating and activating transforming growth factor beta(1). J Exp Med 2001;194:809–821.

    Article  PubMed  CAS  Google Scholar 

  35. Blease K, Jakubzick C, Westwick J, Lukacs N, Kunkel SL, Hogaboam CM: Therapeutic effect of IL-13 immunoneutralization during chronic experimental fungal asthma. J Immunol 2001;166:5219–5224.

    PubMed  CAS  Google Scholar 

  36. Blease K, Jakubzick C, Schuh JM, Joshi BH, Puri RK, Hogaboam CM: IL-13 fusion cytotoxin ameliorates chronic fungal-induced allergic airway disease in mice. J Immunol 2001;167:6583–6592.

    PubMed  CAS  Google Scholar 

  37. Chiaramonte MG, Donaldson DD, Cheever AW, Wynn TA: An IL-13 inhibitor blocks the development of hepatic fibrosis during a T-helper type 2-dominated inflammatory response. J Clin Invest 1999;104:777–785.

    Article  PubMed  CAS  Google Scholar 

  38. Chiaramonte MG, Cheever AW, Malley JD, Donaldson DD, Wynn TA: Studies of murine schistosomiasis reveal interleukin-13 blockade as a treatment for established and progressive liver fibrosis. Hepatology 2001;34:273–282.

    Article  PubMed  CAS  Google Scholar 

  39. Lee JH, Kaminski N, Dolganov G, Grunig G, Koth L, Solomon C, et al.: Interleukin-13 induces dramatically different transcriptional programs in three human airway cell types. Am J Respir Cell Mol Biol 2001;25:474–485.

    PubMed  CAS  Google Scholar 

  40. Homer RJ, Zheng T, Chupp G, He S, Zhu Z, Chen Q, et al.: Pulmonary type II cell hypertrophy and pulmonary lipoproteinosis are features of chronic IL-13 exposure. Am J Physiol Lung Cell Mol Physiol 2002;283:L52-L59.

    PubMed  CAS  Google Scholar 

  41. Hancock A, Armstrong L, Gama R, Millar A: Production of interleukin 13 by alveolar macrophages from normal and fibrotic lung. Am J Respir Cell Mol Biol 1998;18;60–65.

    PubMed  CAS  Google Scholar 

  42. Oriente A, Fedarko NS, Pacocha SE, Huang SK, Lichtenstein LM, Essayan DM: Interleukin-13 modulates collagen homeostasis in human skin and keloid fibroblasts. J Pharmacol Exp Ther 2000;292:988–994.

    PubMed  CAS  Google Scholar 

  43. Richter A, Puddicombe SM, Lordan JL, Bucchieri F, Wilson SJ, Djukanovic R, et al.: The contribution of interleukin (IL)-4 and IL-13 to the epithelial-mesenchymal trophic unit in asthma. Am J Respir Cell Mol Biol 2001;25:385–391.

    PubMed  CAS  Google Scholar 

  44. Wynn TA: IL-13 effector functions. Annu Rev Immunol 2003;21:425–456.

    Article  PubMed  CAS  Google Scholar 

  45. Chiaramonte MG, Mentink-Kane M, Jacobson BA, Cheever AW, Whitters MJ, Goad ME, et al.: Regulation and function of the interleukin 13 receptor alpha 2 during a T helper cell type 2-dominant immune response. J Exp Med 2003;197:687–701.

    Article  PubMed  CAS  Google Scholar 

  46. Wood N, Whitters MJ, Jacobson BA, Witek J, Sypek JP, Kasaian M, et al.: Enhanced interleukin (IL)-13 responses in mice lacking IL-13 receptor alpha 2. J Exp Med 2003;197:703–709.

    Article  PubMed  CAS  Google Scholar 

  47. Mentink-Kane MM, Cheever AW, Thompson RW, Hari DM, Kabatereine NB, Vennervald BJ, et al.: IL-13 receptor {alpha} 2 down-modulates granulomatous inflammation and prolongs host survival in schistosomiasis. Proc Natl Acad Sci USA 2004;101:586–590.

    Article  PubMed  CAS  Google Scholar 

  48. Kawakami K, Taguchi J, Murata T, Puri RK: The interleukin-13 receptor alpha2 chain: an essential component for binding and internalization but not for interleukin-13-induced signal transduction through the STAT6 pathway. Blood 2001;97:2673–2679.

    Article  PubMed  CAS  Google Scholar 

  49. Toru H, Pawankar R, Ra C, Yata J, Nakahata T: Human mast cells produce IL-13 by high-affinity IgE receptor cross-linking: enhanced IL-13 production by IL-4-primed human mast cells. J Allergy Clin Immunol 1998;102:491–502.

    Article  PubMed  CAS  Google Scholar 

  50. Murata T, Obiri NI, Debinski W, Puri RK: Structure of IL-13 receptor: analysis of subunit composition in cancer and immune cells. Biochem Biophys Res Commun 1997;238:90–94.

    Article  PubMed  CAS  Google Scholar 

  51. Murata T, Husain SR, Mohri H, Puri PK: Two different IL-13 receptor chains are expressed in normal human skin fibroblasts, and IL-4 and IL-13 mediate signal transduction through a common pathway. Int Immunol 1998;10:1103–1110.

    Article  PubMed  CAS  Google Scholar 

  52. McKenzie AN, Culpepper JA, de Waal Malefyt R, Briere F, Punnonen J, Aversa G, et al.: Interleukin 13, a T-cell-derived cytokine that regulates human monocyte and B-cell function. Proc Natl Acad Sci USA 1993;90:3735–3739.

    Article  PubMed  CAS  Google Scholar 

  53. McKenzie AN: Regulation of T helper type 2 cell immunity by interleukin-4 and interleukin-13. Pharmacol Ther 2000;88:143–151.

    Article  PubMed  CAS  Google Scholar 

  54. Bochner BS, Klunk DA, Sterbinsky SA, Coffman RL, Schleimer RP. IL-13 selectively induces vascular cell adhesion molecule-1 expression in human endothelial cells. J Immunol 1995;154:799–803.

    PubMed  CAS  Google Scholar 

  55. Zheng T, Zhu Z, Liu W, Lee CG, Chen Q, Homer RJ, Elias JA: Cytokine regulation of IL-13Ralpha2 and IL-13Ralpha1 in vivo and in vitro. J Allergy Clin Immunol 2003;111:720–728.

    Article  PubMed  CAS  Google Scholar 

  56. Kawakami K, Kawakami M, Joshi BH, Puri PK: Interleukin-13 receptor-targeted cancer therapy in an immunodeficient animal model of human head and neck cancer. Cancer Res 2001;61:6194–6200.

    PubMed  CAS  Google Scholar 

  57. Kawakami M, Kawakami K, Puri RK: Apoptotic pathways of cell death induced by an interleukin-13 receptortargeted recombinant cytotoxin in head and neck cancer cells. Cancer Immunol Immunother 2002;50:691–700.

    Article  PubMed  CAS  Google Scholar 

  58. Hogaboam CM, Steinhauser ML, Chensue SW, Kunkel SL: Novel roles for chemokines and fibroblasts in interstitial fibrosis. Kidney Int 1998;54:2152–2159.

    Article  PubMed  CAS  Google Scholar 

  59. Selman M, Pardo A: Idiopathic pulmonary fibrosis: an epithelial/fibroblastic cross-talk disorder. Respir Res 2002;3:3.

    Article  PubMed  Google Scholar 

  60. Lynch JP, 3rd, White E, Flaherty K: Corticosteroids in idiopathic pulmonary fibrosis. Curr Opin Pulm Med 2001;7:298–308.

    Article  PubMed  Google Scholar 

  61. Flaherty KR, Toews GB, Lynch JP, 3rd, Kazerooni EA, Gross BH, Strawderman RL, et al.: Steroids in idiopathic pulmonary fibrosis: a prospective assessment of adverse reactions, response to therapy, and survival. Am J Med 2001;110:278–282.

    Article  PubMed  CAS  Google Scholar 

  62. Gauldie J, Kolb M, Sime PJ: A new direction in the pathogenesis of idiopathic pulmonary fibrosis? Respir Res 2002;3:1.

    Article  PubMed  Google Scholar 

  63. van den Blink B, Jansen HM, Peppelenbosch MP: Idiopathic pulmonary fibrosis: molecular mechanisms and possible therapeutic strategies. Arch Immunol Ther Exp (Warsz) 2000;48:539–545.

    Google Scholar 

  64. Gharaee-Kermani M, Nozaki Y, Hatano K, Phan SH: Lung interleukin-4 gene expression in a murine model of bleomycin-induced pulmonary fibrosis. Cytokine 2001;15:138–147.

    Article  PubMed  CAS  Google Scholar 

  65. King TE, Jr., Schwarz MI, Brown K, Tooze JA, Colby TV, Waldron JA, et al.: Idiopathic pulmonary fibrosis: relationship between histopathologic features and mortality. Am J Respir Crit Care Med 2001;164:1025–1032.

    PubMed  Google Scholar 

Download references

Author information

Author notes

  1. Cory M. Hogaboam PhD

    Present address: Department of Pathology, University of Michigan Medical School, Rm 5216B, Med Sci I, 1301 Catherine Rd, 48109-0602, Ann Arbor, MI

Authors and Affiliations

  1. Laboratory of Molecular Tumor Biology, Division of Cellular and Gene Therapies, Center for Biologics Evaluation and Research, US Food and Drug Administration, Bethesda, MD

    Raj K. Puri

  2. Department of Pathology, University of Michigan Medical School, Rm 5216B, Med Sci I, 1301 Catherine Rd, 48109-0602, Ann Arbor, MI

    Claudia Jakubzick & Steven L. Kunkel

Authors
  1. Claudia Jakubzick
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Steven L. Kunkel
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Raj K. Puri
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Cory M. Hogaboam PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Jakubzick, C., Kunkel, S.L., Puri, R.K. et al. Therapeutic targeting of IL-4-and IL-13-responsive cells in pulmonary fibrosis. Immunol Res 30, 339–349 (2004). https://doi.org/10.1385/IR:30:3:339

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1385/IR:30:3:339

Key words

Search

Navigation